Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Israeli medical company seeks market expansion.
|Total value of the target||N/A|
|Expected target net rate of return after deducting all taxes and fees||N/A|
|Validity period of pending order||365|
Assistant Manager, International Business Advisory
|Project highlights||FDA & CE - 24 patents - initial sales USD 500 million|
The Israeli company holds 24 patents with new and innovative medical devices. The company has been approved by FDA and CE. The company develops and targets minimally invasive cryoablation therapy for women's health and interventional oncology (kidney cancer, lung cancer, liver cancer, bone cancer, and prostate cancer). The system provides outpatient definitive treatment for breast tumors and ablation of other cancerous tumors in the body. Clinical trials have been completed in Europe, America, and Japan. In Europe, Latin America, Asia, and other markets, initial sales are around USD 500 million. The company also targets breast cancer markets. The goal of the company is to seek investment for market expansion.
Enquire for more information about our services, and how we can help solve challenges for your organizationContact Us